Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects
Zandvliet, Anthe, Glasgow, Shirley, Horowitz, Ann, Montgomery, Diana, Marjason, Joanne, Mehta, Anish, Xu, Christine, Vugt, Marianne van, Khalilieh, SauzanneVolume:
53
Language:
english
Journal:
Int. Journal of Clinical Pharmacology and Therapeutics
DOI:
10.5414/CP202176
Date:
February, 2015
File:
PDF, 486 KB
english, 2015